Provention Bio, Inc. (NASDAQ:PRVB) Insider Sells $246,634.05 in Stock

Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) insider Francisco Leon sold 24,015 shares of the business’s stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $10.27, for a total transaction of $246,634.05. Following the completion of the transaction, the insider now owns 1,573,000 shares of the company’s stock, valued at $16,154,710. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Francisco Leon also recently made the following trade(s):

• On Thursday, December 29th, Francisco Leon sold 187,000 shares of Provention Bio stock. The shares were sold at an average price of $10.26, for a total transaction of $1,918,620.00.
• On Tuesday, December 27th, Francisco Leon sold 10,674 shares of Provention Bio stock. The stock was sold at an average price of $10.00, for a total transaction of $106,740.00.
• On Friday, December 23rd, Francisco Leon sold 375 shares of Provention Bio stock. The stock was sold at an average price of $10.00, for a total transaction of $3,750.00.

Provention Bio Trading Up 1.7 %

NASDAQ:PRVB opened at $9.04 on Friday. The firm’s fifty day moving average is $9.30 and its 200-day moving average is $6.70. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.58 and a current ratio of 7.58. Provention Bio, Inc. has a 52 week low of $3.18 and a 52 week high of $10.88. The firm has a market cap of $788.21 million, a P/E ratio of -5.79 and a beta of 2.29.

Provention Bio (NASDAQ:PRVB – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.12. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.88 million. Provention Bio had a negative net margin of 3,791.21% and a negative return on equity of 99.08%. Equities analysts expect that Provention Bio, Inc. will post -1.66 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Provention Bio by 9.2% during the third quarter. BlackRock Inc. now owns 5,030,348 shares of the company’s stock worth $22,637,000 after buying an additional 424,311 shares during the last quarter. Vanguard Group Inc. raised its holdings in Provention Bio by 39.9% during the third quarter. Vanguard Group Inc. now owns 3,604,065 shares of the company’s stock worth $16,219,000 after buying an additional 1,027,113 shares during the last quarter. State Street Corp raised its holdings in Provention Bio by 7.0% during the third quarter. State Street Corp now owns 1,294,425 shares of the company’s stock worth $5,825,000 after buying an additional 85,236 shares during the last quarter. Bioimpact Capital LLC raised its holdings in Provention Bio by 25.0% during the third quarter. Bioimpact Capital LLC now owns 740,344 shares of the company’s stock worth $3,332,000 after buying an additional 147,909 shares during the last quarter. Finally, DG Capital Management LLC raised its holdings in Provention Bio by 19.1% during the second quarter. DG Capital Management LLC now owns 622,568 shares of the company’s stock worth $2,490,000 after buying an additional 100,000 shares during the last quarter. 37.39% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. SVB Leerink upped their price objective on shares of Provention Bio from $16.00 to $19.00 and gave the stock an “outperform” rating in a research report on Monday, November 21st. Chardan Capital upped their price target on shares of Provention Bio from $24.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, November 18th. Jefferies Financial Group upped their price target on shares of Provention Bio from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, November 18th. Finally, Oppenheimer upped their price target on shares of Provention Bio from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 18th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $21.40.

Provention Bio Company Profile

(Get Rating)

Provention Bio, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset.